TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371		Attorney's Docket Number 047763-5018 U.S. Application No. Unassigned
International Application. No.	International Filing Date	Priority Date Claimed
PCT/AU00/00689	June 19, 2000	June 18, 1999

Title of Invention: Detection of Giardia

Applicants For EO/EO/US
Matthias DORSCH and Duncan Veal

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. § 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(l).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. § 371(c)(2))
   a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. § 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)).
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)).
9. ☐ An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. § 371(c)(5)).

Items 11. to 14. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. § 3.28 and § 3.31 is included.
13. ☒ A FIRST preliminary amendment.
    ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☒ Other items or information:
    Published WO 00/78781 (Cover page only, including Abstract)

U.S. APPLICATION NO.	INTERNATIONAL APPLICATION NO.	ATTORNEY DOCKET NUMBER
Unassigned	PCT/AU00/00689	047763-5018

15. ☒ The following fees are submitted:

Basic National Fee (37 C.F.R. § 1.492(a)(1)-(5)):

Search Report has been prepared by the EPO or JPO.....$890.00
International preliminary examination fee paid to USPTO (37 C.F.R. § 1.482).....$710.00
No international preliminary examination fee paid to USPTO (37 C.F.R. § 1.482) but international search fee paid to USPTO (37 C.F.R. § 1.445(a)(2)).....$740.00
Neither international preliminary examination fee (37 C.F.R. § 1.482) nor international search fee (37 C.F.R. § 1.445(a)(2)) paid to USPTO.....$1,040.00
International preliminary examination fee paid to USPTO (37 C.F.R. § 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = $1040.00

Surcharge of $130.00 for furnishing the oath or declaration later than ☐ **20** ☒ **30** months from the earliest claimed priority date (37 C.F.R. § 1.492(e)). $

Claims	Number Filed	Number Extra	Rate	
Total Claims	18 - 20 =		X $18.00	$
Independent Claims	2 - 3 =		X $84.00	$
Multiple dependent claim(s) (if applicable)			+ $280.00	$
		TOTAL OF ABOVE CALCULATIONS		$
		Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 C.F.R. §§ 1.9, 1.27, 1.28)		-$
		SUBTOTAL =		**$ 1040.00**
Processing fee of $130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).				+$
		TOTAL NATIONAL FEE =		**$ 1040.00**
Fee for recording the enclosed assignment (37 C.F.R. § 1.21(h)). The Assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§ 3.28, 3.31). $40.00 per property				$
		TOTAL FEES ENCLOSED =		**$1040.00**
		Amount to be refunded		$
		Amount to be charged		$

a. ☐ A check in the amount of $_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 50-0310 in the amount of **$ 1040.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Customer No. 09629
SEND ALL CORRESPONDENCE TO:
Morgan, Lewis & Bockius LLP
1800 M Street, N.W.
Washington, D.C. 20036
Telephone: (202) 467-7000
Facsimile: (202) 467-7176

Elizabeth C. Weimar
Elizabeth C. Weimar
Reg. No. 44,478

Submitted: December 18, 2001

PATENT
ATTORNEY DOCKET NO. 047763-5018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Matthias DORSCH, et al.	
U.S. Application No.: To Be Assigned	Group Art Unit: Unassigned
Date of National Stage Entry : December 18, 2001	Examiner: Unassigned
Based on PCT/AU00/00689 Filed : June 19, 2000	
For: **DETECTION OF GIARDIA**	

Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above-identified application on the merits, please amend the application, without prejudice, as follows:

IN THE CLAIMS:

Please amend claims 1, 3, 6, 9-10, and 14-17 as follows:

1. (AMENDED) An oligonucleotide molecule for the detection of *Giardia lamblia (G. lamblia)*, wherein the oligonucleotide molecule hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia*.

3. (AMENDED) The oligonucleotide molecule according to claim 1 selected from the group consisting of oligonucleotides having the following nucleotide sequences:

GCG TCC CGG GTG AGC GGG (SEQ ID NO: 1):

GCC CGC GGG CGC CCG CCC (SEQ ID NO: 2)

TGG GCC CGC CTC GCT CGC (SEQ ID NO: 3):

CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4):

GCG GGT CCA ACG GGC CTG (SEQ ID NO: 5):

CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6): and

oligonucleotides comprising a part of the sequences above having at least ten bases which hybridise to unique rDNA/rRNA sequences of *G. lamblia*.

6. (AMENDED) The oligonucleotide molecule according to claim 1 being detectably labelled.

9. (AMENDED) The oligonucleotide molecule according to claim 7 wherein the fluorochrome is selected from the group consisting of fluorescein isothiocyanate, also known as FITC. green, cyanine dyes Cy2, Cy3, Cy3.5, Cy5, Cy5.5 that range from green to far red, and Texas Red.

10. (AMENDED) A method for the detection of the presence of viable cells of *G. lamblia* in a sample comprising the steps of:

(a) adding to the sample an effective amount of a probe consisting of a detectably labelled oligonucleotide molecule which hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia:*

(b) creating and maintaining conditions effective for hybridisation of the probe to the 18S rDNA/rRNA of any *G. lamblia* cells present in the sample; and

(c) detecting hybridisation of the probe and *G. lamblia* nucleotides.

14. (AMENDED) The method according to claim 10 comprising detection via fluorescence *in situ* hybridization (FISH) in which the oligonucleotide probe is labelled with fluorochrome and after hybridization, the resulting fluorescent-labelled cell is detected by epifluorescence microscopy or flow cytometry.

15. (AMENDED) The method according to claim 10 wherein at least two different oligonucleotide probes are used and are distinguished by the use of different labels on each probe.

16. (AMENDED) The method according to claim 15 wherein the oligonucleotide probes are labelled with different fluorochromes and are detected by flow cytometry.

17. (AMENDED) The method according to claim 10 wherein the sample is an environmental sample.

REMARKS

The changes to the above claims have been made so as to eliminate multiple claim dependencies and to present claim language more conventional for practice in the United States including presentation of correct grammar and verb tense. These changes do not introduce new matter, nor do they narrow the subject matter of the claims presented and examined in the corresponding International Application.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: Elizabeth C. Weimar

Dated: December 18, 2001
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, NW
Washington, DC 20036-5869
(202) 467-7000

Marked up version of amended claims

1. An oligonucleotide molecule for the detection of *Giardia lamblia (G. lamblia)*, wherein the oligonucleotide molecule hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia*.

3. The oligonucleotide molecule according to claim 1 [or 2] selected from the group consisting of oligonucleotides having the following nucleotide sequences:

GCG TCC CGG GTG AGC GGG (SEQ ID NO: 1):

GCC CGC GGG CGC CCG CCC (SEQ ID NO: 2)

TGG GCC CGC CTC GCT CGC (SEQ ID NO: 3):

CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4):

GCG GGT CCA ACG GGC CTG (SEQ ID NO: 5):

CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6): and

oligonucleotides comprising a part of the sequences above having at least ten bases which hybridise to unique rDNA/rRNA sequences of *G. lamblia*.

6. The oligonucleotide molecule according to [any one of] claim[s] 1 [to 5] being detectably labelled.

9. The oligonucleotide molecule according to claim 7 wherein the fluorochrome is selected from the group consisting of fluorescein isothiocyanate, also known as [(] FITC. green[)], cyanine dyes Cy2, Cy3, Cy3.5, Cy5, Cy5.5 that range [(ranging] from green to far red[)], and Texas Red.

10. A method for the detection of the presence of viable cells of *G. lamblia* in a sample comprising the steps of:

(a) adding to the sample an effective amount of a probe consisting of a detectably labelled oligonucleotide molecule which hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia:*

(b) creating and maintaining conditions effective for [allowing] hybridisation of the probe to the 18S rDNA/rRNA of any *G. lamblia* cells present in the sample; and

(c) detecting hybridisation of the probe and *G. lamblia* nucleotides.

14. The method according to [any one of] claim[s] 10 [to 13] comprising detection via [is used in combination with] fluorescence *in situ* hybridization (FISH) in which the oligonucleotide probe is labelled with fluorochrome and after hybridisation, the resulting fluorescent-labelled cell is detected by epifluorescence microscopy or flow cytometry.

15. The method according to [any one of] claim[s] 10 [to 14] wherein [several] at least two different oligonucleotide probes are used and are distinguished by the use of different labels on each probe.

16. The method according to claim 15 wherein the oligonucleotide probes are labelled with different fluorochromes and are detected by flow cytometry.

17. The method according to [anyone of] claim[s] 10 [to 16] wherein the sample is an environmental sample.

10/018211
JC07 Rec'd PCT/PTO 18 DEC 2001

WO 00/78781 PCT/AU00/00689

Detection of Giardia

Technical Field

The present invention is directed to the detection of parasite pathogens. particularly *Giardia lamblia*, using molecular probes.

Background Art

Fluorescent *in situ* hybridisation (FISH) employing nucleic acid probes is one of the most advanced techniques for detection and enumeration of microorganisms. The technique emerged in the early nineties and since then has been improved rapidly and is being used for a wide range of applications which include diagnostics in clinical microbiology and analysis of microbial community structure in environmental and industrial microbiology/biotechnology. Although widely used for bacteria. very few publications describe methods for detection and enumeration of protozoan pathogens. The design of oligonucleotide probes requires skill and experience to determine accessible regions of rRNA in native ribosomes. An additional problem of successful FISH for protozoa is the development of hybridisation protocols that allow oligonucleotide probes to penetrate protozoa cell walls which are fundamentally different to bacterial cell walls. Moreover. the composition of bacterial cell walls has been well documented whereas little knowledge exists about the structure of the cyst walls of protozoa like *Cryptosporidium* spp. *Giardia* spp and related organisms.

To date, monoclonal antibodies (mabs) are the most important and widely applied tool for detection of *Giardia* cysts in water samples. The vast majority of commercially available antibodies show a lack of specificity as the antibodies detect all *Giardia* spp including species that do not infect humans. As a positive antibody reaction does not allow any conclusion regarding the viability (infectivity) of the cysts, viability stains (DAPI, PI) have to be used in conjunction with antibodies.

Oligonucleotide probes for FISH have several advantages over mabs in that probes are significantly cheaper to produce and are more stable as probes can be stored for long periods without loosing reactivity or specificity. Furthermore, correctly designed probes should only detect cysts of *Giardia lamblia* and no other species unable to infect humans. Probes target rRNA and will potentially only detect viable cysts which are able to cause infection. As non-viable (dead) cyst contain no or only small amounts of rRNA. it is envisaged that these cysts will not undergo detection.

The present inventors have developed specific oligonucleotides suitable for detection of potentially viable *Giardia* spp cysts and hybridisation protocols that allow permeabilization of the cyst walls and enable oligonucleotide probes to reach their ribosomal nucleic acid targets.

Disclosure of Invention

In a first aspect, the present invention consists in an oligonucleotide molecule for the detection of *Giardia lamblia* (*G. lamblia*), the oligonucleotide molecule hybridises to unique 18S rDNA/rRNA sequences of *G. lamblia*.

Preferably, the oligonucleotide molecule hybridises specifically to unique 18S rDNA/rRNA sequences of *G. lamblia* under medium to high stringency conditions (Sambrook *et al*., 1989 Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Laboratory Press). In many cases, however, conditions of high stringency can be used to ensure specific hybridisation to unique *G. lamblia* 18S rDNA/rRNA sequences.

In a preferred embodiment of the first aspect of the present invention, the oligonucleotide molecule is selected from the group of oligonucleotides having one or more of the following nucleotide sequences:

Giar-1	GCG TCC CGG GTG AGC GGG (SEQ ID NO: 1)
Giar-2	GCC CGC GGG CGC CCG CCC (SEQ ID NO: 2)
Giar-3	TGG GCC CGC CTC GCT CGC (SEQ ID NO: 3)
Giar-4	CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4)
Giar-5	GCG GGT CCA ACG GGC CTG (SEQ ID NO: 5)
Giar-6	CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6)

or comprising a part of the sequences, typically at least 10 bases in length, Giar-1 to Giar-6 above so as to allow specific hybridisation to unique 18S rRNA sequences of *G. lamblia*.

In a further preferred embodiment, the oligonucleotide molecules are Giar-4 or Giar-6.

Preferably, the oligonucleotide molecules according to the invention are detectably labelled so that the oligonucleotides may be utilised as probes in hybridisation assays. It will be appreciated, however, that oligonucleotide molecules which are not labelled may be used, for example, in a polymerase chain reaction (PCR) to amplify a part of the rDNA of *G. lamblia*.

Stringent conditions are usually defined as those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M NaCl/0.0015 M sodium citrate/0/1% NaDodSO$_4$ at 65^{0}C; (2) employ during hybridisation a denaturing agent such as formamide, for example, up to 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 nM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42^{0}C; or (3) employ up to 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 g/ml), 0.1% SDS and 10% dextran sulfate at 42^{0}C in 0.2 x SSC and 0.1% SDS.

Clarification of the term "18S rDNA/rRNA" for *Giardia lamblia* and *Giardia* spp. is provided as follows. The RNA molecule in question is very unusual. With approximately 1450 nucleotides, the 18S RNA molecule is significantly shorter than the 18S rRNA of other eukaryotes and in respect of sizes resembles the 16S rRNA of bacteria (Sogin et al. 1989 Phylogenetic meaning of the kingdom concept: An unusual ribosomal RNA from *Giardia lamblia*. Science 243: 75-77). However, as determined by sequence homology *Giardia* appears to be an eukaryote representing a phylogenetically 'ancient' group of species. In the following, the term "18S rRNA/DNA" will be used for all eukaryotic sequences that were examined for the purpose of designing *Giardia lamblia* specific probes.

In a second aspect, the present invention provides a method for the detection of the presence of viable cells of *G. lamblia* in a sample, the method comprising the steps of:

(a) adding to the sample a probe comprising a detectably labelled oligonucleotide molecule according to the first aspect of the present invention;

(b) allowing hybridisation of the probe to the 18S rDNA/rRNA of any *G. lamblia* cells present in the sample; and

(c) detecting hybridisation of the probe.

Detection of any hybridisation of the probe to 18S rDNA/rRNA in the sample is indicative of the presence of viable cells of *G. lamblia* in the sample.

The sample can be any sample where there is concern that *G. lamblia* may be present Samples include environmental, water sources, waste

materials. medical and body fluids. Examination of drinking water samples are particularly applicable for the present invention.

In a preferred embodiment. the method is used in combination with fluorescence *in situ* hybridisation (FISH) in which the oligonucleotide probe is labelled with a fluorochrome and after hybridisation. the resulting fluorescent cell is detected by epifluorescence microscopy or flow cytometry.

Suitable fluorochromes for the probes include but not limited to fluorescein isothiocyanate (FITC. green), cyanine dyes Cy2. Cy3, Cy3.5. Cy5. Cy5.5 (ranging from green to far red) or Texas Red. Other labels include radio-isotopes phosphorus ^{32}P and ^{33}P and sulfur ^{35}S. Another option is conjugation of probes to biotin and then add streptavidin-linked horseradish peroxidase (HRP) to the hybridisation reaction in order to enhance the signal via tyramide signal amplification (TSA).

In order to improve the hybridisation of the probe to the nucleic acid of the cell. the present inventors have found that adding formamide (preferably around 20% v/v) to the hybridisation buffer increases the stringency sufficiently to eliminate cross reactions of the probes with *Giardia muris*). Other agents which act in a similar manner would also be suitable to assist in specific hybridisation.

In a further preferred embodiment of the second aspect of the present invention. several different oligonucleotide probes are used and are distinguished by the use of different labels on each probe. More preferably the oligonucleotide probes are labelled with different fluorochromes and detected by flow cytometry.

While it is preferred that the probes are fluorescently labelled. it is to be understood that other known forms of labelling may be used within the broad scope of the present invention. Examples of other forms of labelling are radioactivity and chemiluminescence.

In a third aspect. the present invention provides an oligonucleotide molecule which hybridizes to *G. lamblia* 18S rDNA/rRNA sequences under medium to high stringency conditions wherein the oligonucleotide molecules hybridizes to at least one of target regions of *G. lamblia* rDNA having the following nucleotide sequences:

CCC GCT CAC CCG GGA CGC (SEQ ID NO: 7)

GGG CGG GCG CCC GCG GGC (SEQ ID NO: 8)

GCG AGC GAG GCG GGC CCA (SEQ ID NO: 9)

GTA GTT GGC CCC CCG CCG (SEQ ID NO: 10)
CAG GCC CGT TGG ACC CGC (SEQ ID NO: 11)
CGC GCC GCG GCA GCC CCG (SEQ ID NO: 12).

The oligonucleotide molecules and methods of the present invention may be used to detect the presence in a sample of any type of viable cell of *G. lamblia*. Normally only oocysts will be found in environmental samples. Other cell types. trophozoites may. however. be found and detected in clinical samples.

The oligonucleotide probes according to the present invention have tested successfully in the inventors' laboratories. Probes were used on samples that underwent IMS. staining with fluorescently labelled antibodies and sorting of positive particles on a membrane via flow cytometry. FISH was then carried out with these membranes in order to determine species identity and viability of the cysts and the membranes examined by epi-fluorescence microscopy once the hybridisation reaction is completed.

Further. it has been established that the probes specifically detect cysts of *Giardia lamblia*. Weak cross reactions were observed when the probes were hybridised against cysts of the closely related species *Giardia muris*. Cross reactions were subsequently eliminated by modifying the hybridisation buffer in a manner that increases the stringency of the hybridisation.

The present inventors demonstrated earlier that an excellent correlation exists between the FISH signal intensity obtained from *Cryptosporidium parvum* oocysts and viability of the oocysts as measured by excystation (Vesey *et al.* 1995 The use of a ribosomal RNA targeted oligonucleotide probe for fluorescent labelling of viable *Cryptosporidium parvum* oocysts. *J. Appl. Microbiol.* 85: 429-440). It is likely that *Giardia* cysts having lost their viability through ageing. which includes degradation of the rRNAs. the target of the oligonucleotide probes. will not show any fluorescent signal.

Throughout this specification. unless the context requires otherwise. the word "comprise". or variations such as "comprises" or "comprising". will be understood to imply the inclusion of a stated element. integer or step. or group of elements. integers or steps. but not the exclusion of any other element. integer or step. or group of elements. integers or steps.

Any description of prior art documents herein is not an admission that the documents form part of the common general knowledge of the relevant art in Australia.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples.

Modes for Carrying Out the Invention

Design of Oligonucleotide Probes

A brief explanation of the systematics of the genus *Giardia* is provided as follows. *Giardia lamblia* is the only species of the genus that is known to cause disease in humans. Some controversy still surrounds the systematics of the species which is also referred to as *Giardia duodenalis* or *Giardia intestinalis* (Lu *et al.* 1998 Molecular comparison of *Giardia lamblia* isolates. Int. J. Parasitol. **28**: 1341-1345). Other representatives of the genus *Giardia* described to date are *Giardia agilis* from amphibians and *Giardia muris* from rodents. birds and reptiles (Meyer 1994 *Giardia* as an organism. P 3-13. In: RCA. Thompson. J.A. Reynoldsen. A.J. Lymbery (eds.) *Giardia*: From molecules to disease. CAB International. Wallingford. Oxon. UK). *Giardia ardea* from herons (Erlandsen *et al.* 1990 Axenic culture and characterization of *Giardia ardea* from the great blue heron (*Ardea herodias*). J. Prasitol. **76**: 717-724) and *Giardia microti* from muskrats and voles (van Keulen *et al.* 1998 The sequence of *Giardia* small subunit rRNA shows that voles and muskrats are parasitized by a unique species *Giardia microti*. J. Parasitol. **84**: 294-300).

Sequence information of 18S rDNA of *Giardia lamblia* and phylogenetically closely related species was obtained from GenBank through ANGIS (Australian National Genomic Information Service) at Sydney University. All relevant sequences of *Giardia* spp. as available in April 2000 were examined. Sequences retrieved included:

Z17210-*Giardia ardea*
M54878-*Giardia lamblia*:
U09492-Giardia lamblia
U09491-*Giardia lamblia*
AF006677-*Giardia microti*
AF006676-*Giardia microti*
X65063-*Giardia muris*
U20351-*Giardia*. sp.
L16997-*Cryptosporidium parvum*:

L19069-*Cryptosporidium muris*:
L19068-*Cryptosporidium baileyi*:
U40261-*Cyclospora* sp.:
U40262-*Eimeria mitis*:
U40264-*Eimeria tenella*:
U40263-*Eimeria nieschulzi*:
U26532-*Nosema furnucalis*:
U26533-*Nosema ceranae*:
X73894-*Nosema apis*: and
L39110-*Ichtyosporidium*

Sequences were aligned using the program ClustalW and screened for diagnostic regions. e.g. regions that specifically discriminated *Giardia lamblia* from the other species included in the alignment. Six target regions were identified as listed below. The positions of the nucleotides given are not based on any internationally recognised numbering system but refer to the numbering for the *Giardia lamblia* 18S rRNA (designated 16S rRNA in the reference) given in a secondary structure model published by Sogin *et al.* in 1989 (Phylogenetic meaning of the kingdom concept: An unusual ribosomal RNA from *Giardia lamblia*. Science **243:** 75-77). In accord with international agreements. all sequences listed. including oligonucleotide sequences, are shown in 5'-3' orientation.

Target Regions

Target regions (rDNA) were identified as follows:

1. CCC GCT CAC CCG GGA CGC (Position 57-74) (SEQ ID NO: 7)
2. GGG CGG GCG CCC GCG GGC (Position 166-183) (SEQ ID NO: 8)
3. GCG AGC GAG GCG GGC CCA (Position 391-408) (SEQ ID NO: 9)
4. GTA GTT GGC CCC CCG CCG (Position 508-525) (SEQ ID NO: 10)
5. CAG GCC CGT TGG ACC CGC (Position 552-569) (SEQ ID NO: 11)
6. CGC GCC GCG GCA GCC CCG (Position 596-613) (SEQ ID NO: 12)

Due to the fact that *G. lamblia* shows a very unusual 18 rRNA regarding sequence and secondary structure. it appeared reasonable to assume that the probes are *G. lamblia* specific and will not show cross reactions with other protozoans under moderately stringent hybridisation conditions. Table 1 shows a comparison of the target regions for the two functional FISH probes

Giar-4 and Giar-6 from all *Giardia* spp. 18S rDNA/RNA target sequences available. A cross reaction observed from probe Giar-4 with *G. muris*, probably the phylogenetically closest related species to *G. lamblia*, occurred under low stringency hybridisation and was eliminated by increased stringency through 20 % formamide in the hybridisation buffer. The alignment of published sequences used to design the probes showed that the corresponding target region of Giar-4 on the *G. muris* 18S rRNA shows eight mismatches and one deletion compared to the target region on the *G. lamblia* 18S rRNA. A corresponding target region for Giar-6 does not exist on the *G. muris* 18S rRNA. It appears that a large part of the rRNA in this region was deleted during the evolution of *G. muris*.

From database searches, it would appear that the Giar-4 and Giar-6 probes might cross react with a species designated *G. microti*, isolated from muskrats and voles. These sequences show a very high overall sequence homology up to 96.8 % to the *G. lamblia* sequence. It appears questionable to describe the isolate as a species different to *G. lamblia* as other *Giardia* spp. share as little as 72-75 % sequence homology *G. lamblia*. Given that it has not been demonstrated to date that *G. microti* does not infect humans, it appears possible that the organism is in fact *G. lamblia* or a subspecies of *G. lamblia* which is supported by the high sequence homology of the 18S rRNAs. According to literature available, *G. microti* is not a generally recognised species and the fact that Giar-4 and Giar-6 will detect the organism is unlikely to contradict the finding that the probes according to the present invention are *G. lamblia* specific.

TABLE 1: Comparison of the target regions of 'Giar-4' and 'Giar-6' on the 16S rDNA of *Giardia* spp.*

Species/ Accession	Target 'Giar-4'	Target 'Giar-6'
G. lamblia M54878	GTAG TTGGCCCCCCGCCG	CGCGC CGCGGCA GCCCCG
G. lamblia U09492	GTAG TTGGCCCCCCGCCG	CGCGC CGCGGCA GCCCCG
G. lamblia U09491	GTAG TTGGCCCCCCGCCG	CGCGC CGCGGCA GCCCCG
G. microti AF006677	GTAG TTGGCCCCCCGCCG	CTCGC CGCGGCA GCCCCG
G. microti AF006676	GTAG TTGGCCCCCCGCCG	CGCGC CGCGGCA GCCCCG
G. ardea Z17210	GCAGGCGTCGCGCGGCGCTG	TGGACCTACCGCCCGGGACGGCG
G. sp. U20351	GGCGCTGCTG CTGCAGTTA	CGC C CGGGAC GCGCG
G. muris X65063	GGAGTCGAGACGTC CAG	Not Applicable**

Nucleotide residues printed in bold indicate mismatch to the *G. lamblia* target sequences of 'Giar-4' and 'Giar-6'. blank space represents nucleotide deletions

*Analysis include all 16S rDNA sequences of *Giardia* spp. available through GenBank in April 2000

**Comparative sequence analysis and secondary structure modeling led to the conclusion that no corresponding target region exists on the 16S rRNA of *G. muris*

FISH Probes

Fluorescently labelled oligonucleotide probes were produced for the target regions as shown above. Naturally, sequences of the oligonucleotides are the reverse complement of the target regions:

Giar-1	GCG TCC CGG GTG AGC GGG	(SEQ ID NO: 1)
Giar-2	GCC CGC GGG CGC CCG CCC	(SEQ ID NO: 2)
Giar-3	TGG GCC CGC CTC GCT CGC	(SEQ ID NO: 3)
Giar-4	CGG CGG GGG GCC AAC TAC	(SEQ ID NO: 4)
Giar-5	GCG GGT CCA ACG GGC CTG	(SEQ ID NO: 5)
Giar-6	CGG GGC TGC CGC GGC GCG	(SEQ ID NO: 6)

Preliminary investigations including a universal eukaryotic probe as a positive control showed that only probes Giar-4 and Giar-6 were suitable for FISH as the other probes yielded no or very weak signals. Subsequently, Giar-4 and Giar-6 were employed for further testing and refinement of hybridisation conditions. The other four probes, Giar-1, Giar-2, Giar-3, and Giar-5, however, can be employed for specific detection of *Giardia lamblia* rRNA or rDNA in techniques that target free nucleic acids such as Polymerase Chain Reaction (PCR) assays or dot blot hybridisations.

RESULTS

Commercially available viable *Giardia lamblia* cysts were used. Aliquots of cysts were stored at -20°C in 50% ethanol and 50% phosphate buffered saline (PBS), pH 7.2. This method of fixation enables long term storage (> 1 year) prior to hybridisation experiments without diminished FISH signal due to degradation of ribosomal nucleic acids.

METHOD

Protocol for Fluorescent *in situ* Hybridisation in 1.5 ml Tubes

A suspension containing cysts was centrifuged for 5 min and the supernatant discarded. A centrifugal force greater than 1200 x g should be avoided as this will cause many cysts to rupture.

Resuspend cysts in 50% ethanol and 50% PBS, incubate at 80°C for 20 min.

Centrifuge cysts, discard supernatant and resuspend in FISH buffer (0.9 M NaCl, 10 mM Tris/HCl, pH 7.2, 0.1% SDS, 20% formamide). Adding 20% formamide to the hybridisation buffer increased the stringency

sufficiently to eliminate the above mentioned cross reactions of the probes with *Giardia muris* containing 1 picomol per microliter of each fluorescently labelled probe Giar-4 and Giar-6.

Incubate at 80°C for 2 min. transfer to 48°C water bath and incubate 60 min.

Terminate hybridisation by adding ice cold PBS. spin. discard supernatant and resuspend cysts in ice cold PBS. Cysts are then ready to be examined.

The hybridisation protocol as detailed above can be applied for cysts concentrated via IMS. stained with FITC-labelled antibodies and sorted on filters by flow cytometry. Alternatively. *Cryptosporidium parvum* oocysts and *Giardia lamblia* cysts can be detected simultaneously by applying the specific probes described here in conjunction with *Cryptosporidium parvum* specific probes and hybridisation protocols (Deere *et al.* 1998 Rapid method for fluorescent *in situ* ribosomal RNA labelling of *Cryptosporidium parvum*. *J. Appl. Microbiol.* 85: 807-818: Vesey *et al.* 1998 The use of a ribosomal RNA targeted oligonucleotide probe for fluorescent labelling of viable *Cryptosporidium parvum* oocysts. *J. Appl. Microbiol.* 85: 429-440).

Modifications

Possible modifications of the invention is the application of methods that allow amplification of the fluorescent FISH signal. In brief. molecular beacons are modified. fluorescently labelled oligonucleotides that can only emit a fluorescent signal when attached to their specific nucleic acid target. No signal will be obtained from probes that are bound non-specifically to any other matter in a sample. In essence. increased signal strength is achieved by eliminating or at least drastically reducing background signals (Schofield *et al.* 1997 Molecular beacons: Trial of a fluorescence-based solution hybridization technique for ecological studies with ruminal bacteria. *Appl. Envir. Microbiol.* 63: 1143-1147). Tyramide signal amplification (Schönhuber *et al.* 1997 Improved sensitivity of whole cell hybridization by the combination of horseradish peroxidase-labelled oligonucleotides and tyramide signal amplification. *Appl. Envir. Microbiol.* 63: 3268-3273) utilises unlabelled oligonucleotide probes that are conjugated to horseradish peroxidase (HRP). After the hybridisation reaction is completed, the hybridisation buffer is removed and replaced by a buffer solution containing HRP substrate conjugated to a fluorescent dye. Subsequently. HRP linked to

oligonucleotides converts the substrate into a fluorescent precipitate that accumulates in the target cells.

The present invention is a continuation of the development of specific oligonucleotide probes for detection and enumeration of protozoan pathogens in water via fluorescent *in situ* hybridisation (FISH). The investigations led to the first specific FISH probes for detection of viable *Cryptosporidium parvum* oocysts (WO 96/34978 entitled Method for the Detection of Viable *Cryptosporidium parvum* oocysts). Comparative sequence analysis of the 18S ribosomal DNA (rDNA) from *Giardia lamblia* and closely related species (in terms of sequence homology) and secondary structure analysis was used to determine the accessibility of the potential target region resulted in the oligonucleotide probes disclosed. Based on the above investigations, six potentially specific FISH probe sequences were determined. The probes were produced and tested on trophozoites of *Giardia lamblia*. Two of these probes (designated Giar-4 and Giar-6) yielded a strong fluorescent signal and showed the same result when hybridised against potentially viable cysts. The remaining four probes showed either very weak or no fluorescence at all and were subsequently omitted from further FISH experiments. However, these four probes can be employed for specific detection of *Giardia lamblia* rRNA or rDNA in techniques that target free nucleic acids such as Polymerase Chain Reaction (PCR) assays or dot blot hybridisations.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. An oligonucleotide molecule for the detection of *Giardia lamblia* (*G. lamblia*), the oligonucleotide molecule hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia*.

2. The oligonucleotide molecule according to claim 1 which hybridises to unique 18S rDNA/rRNA sequences of *G. lamblia* under conditions of high stringency.

3. The oligonucleotide molecule according to claim 1 or 2 selected from the group consisting of oligonucleotides having the following nucleotide sequences:

GCG TCC CGG GTG AGC GGG (SEQ ID NO: 1):
GCC CGC GGG CGC CCG CCC (SEQ ID NO: 2):
TGG GCC CGC CTC GCT CGC (SEQ ID NO: 3):
CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4):
GCG GGT CCA ACG GGC CTG (SEQ ID NO: 5):
CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6): and

oligonucleotides comprising a part of the sequences above having at least ten bases which hybridise to unique rDNA/rRNA sequences of *G. lamblia*.

4. The oligonucleotide molecule according to claim 3 comprising the nucleotide sequence:

CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4).

5. The oligonucleotide molecule according to claim 3 comprising the nucleotide sequence:

CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6).

6. The oligonucleotide molecule according to any one of claims 1 to 5 being detectably labelled.

7. The oligonucleotide molecule according to claim 6 wherein the label is selected from the group consisting of fluorochrome, radioisotope, and chemical.

8. The oligonucleotide molecule according to claim 7 wherein the label is a fluorochrome.

9. The oligonucleotide molecule according to claim 7 wherein the fluorochrome is selected from the group consisting of fluorescein isothiocyanate (FITC, green), cyanine dyes Cy2, Cy3, Cy3.5, Cy5, Cy5.5 (ranging from green to far red), and Texas Red.

10. A method for the detection of the presence of viable cells of *G. lamblia* in a sample, the method comprising the steps of:

(a) adding to the sample a probe consisting of a detectably labelled oligonucleotide molecule which hybridises under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia*:

(b) allowing hybridisation of the probe to the 18S rDNA/rRNA of any *G. lamblia* cells present in the sample: and

(c) detecting hybridisation of the probe.

11. The method according to claim 10 wherein the probe is selected from the group consisting of oligonucleotides having one or more of the following nucleotide sequences:

GCG TCC CGG GTG AGC GGG (SEQ ID NO: 1)
GCC CGC GGG CGC CCG CCC (SEQ ID NO: 2)
TGG GCC CGC CTC GCT CGC (SEQ ID NO: 3)
CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4)
GCG GGT CCA ACG GGC CTG (SEQ ID NO: 5)
CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6)

and oligonucleotides comprising a part of the sequences above having at least ten bases which hybridise to unique rDNA/rRNA sequences of *G. lamblia*.

12. The method according to claim 11 wherein the oligonucleotide molecule comprises the nucleotide sequence:

CGG CGG GGG GCC AAC TAC (SEQ ID NO: 4).

13. The method according to claim 11 wherein the oligonucleotide molecule comprises the nucleotide sequence:

CGG GGC TGC CGC GGC GCG (SEQ ID NO: 6).

14. The method according to any one of claims 10 to 13 is used in combination with fluorescence *in situ* hybridisation (FISH) in which the oligonucleotide probe is labelled with fluorochrome and after hybridisation, the resulting fluorescent-labelled cell is detected by epifluorescence microscopy or flow cytometry.

15. The method according to any one of claims 10 to 14 wherein several different oligonucleotide probes are used and are distinguished by the use of different labels on each probe.

16. The method according to claim 15 wherein the oligonucleotide probes are labelled with different fluorochromes and detected by flow cytometry.

17. The method according to any one of claims 10 to 16 wherein the sample is an environmental sample.

18. An oligonucleotide molecule which hybridizes to *G. lamblia* 18S rDNA/rRNA sequences under medium to high stringency conditions, wherein the oligonucleotide molecule hybridizes to at least one of target regions of *G. lamblia* rDNA having the following nucleotide sequences:

GCC GCT CAC CCG GGA CGC (SEQ ID NO: 7);
GGG CGG GCG CCC GCG GGC (SEQ ID NO: 8);
GCG AGC GAG GCG GGC CCA (SEQ ID NO: 9);
GTA GTT GGC CCC CCG CCG (SEQ ID NO: 10);
CAG GCC CGT TGG ACC CGC (SEQ ID NO: 11);
CGC GCC GCG GCA GCC CCG (SEQ ID NO: 12).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78781 A1

(51) International Patent Classification[7]: C07H 21/02, 21/04, C12N 15/11, C12Q 1/68

(21) International Application Number: PCT/AU00/00689

(22) International Filing Date: 19 June 2000 (19.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PQ 1056 18 June 1999 (18.06.1999) AU

(71) Applicant *(for all designated States except US)*: **MACQUARIE RESEARCH LTD** [AU/AU]; Becton Dickinson Building, 2nd Floor, Research Park Drive, Macquarie University, Sydney, NSW 2066 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DORSCH, Matthias, Rudolf** [DE/AU]; 2B Morrice Street, Lane Cove, NSW 2066 (AU). **VEAL, Duncan, Adam** [GB/AU]; 70 Finlay Road, Turramurra, NSW 2074 (AU).

(74) Agent: **F B RICE & CO**; 605 Darling Street, Balmain, NSW 2041 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/78781 A1

(54) Title: DETECTION OF GIARDIA

(57) Abstract: Oligonucleotide molecules for the detection of *Giardia lamblia* (*G. lamblia*) which molecules hybridise under medium to high stringency conditions to unique 18S rDNA/rRNA sequences of *G. lamblia*, and methods for the detection of the presence of viable cells of *G. lamblia* in samples using the oligonucleotide molecules.

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 047763-5018

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

DETECTION OF GIARDIA

The specification of which:

is attached hereto; or

was filed as United States application Serial No. _____ on _____ and was amended on _____ (if applicable); or

was filed as PCT international application Number PCT/AU00/00689 on June 19, 2000 and was amended under PCT Article 19 On _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations Section1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate or Section 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign applications(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
Australia	PQ1056	18 June 1999	☒ Yes ☐ No
			☐ Yes ☐ No
			☐ Yes ☐ No
			☐ Yes ☐ No

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)
ATTORNEY DOCKET NO.: 047763-5018

I hereby claim the benefits under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.	U.S. FILING DATE:

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. OR PCT INTERNATIONAL APPLICATIONS		STATUS (Check One)		
APPLICATION NO.	FILING DATE	PATENTED	PENDING	ABANDONED
		☐	☐	☐
		☐	☐	☐
		☐	☐	☐
		☐	☐	☐

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:

202-739-3000

Combined Declaration for Patent Application and Power of Attorney - (Continued)
(Includes Reference to PCT International Applications)
ATTORNEY DOCKET NO.: 047763-5018

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	Matthias Rudolf DORSCH	
RESIDENCE & CITIZENSHIP	New South Wales, Australia AUX	COUNTRY OF CITIZENSHIP Australia
POST OFFICE ADDRESS	4 Wanda Court, Greensborough, VIC 3088	
FIRST OR SOLE INVENTOR'S SIGNATURE: Matthias Dorsch		DATE 1/04/02
FULL NAME OF SECOND INVENTOR	Duncan Adam VEAL	
RESIDENCE & CITIZENSHIP	New South Wales, Australia AUX	COUNTRY OF CITIZENSHIP Australia
POST OFFICE ADDRESS	70 Pinley Road, Turramurra, New South Wales, 2074, Australia	
SECOND INVENTOR'S SIGNATURE: DVP		DATE 8/04/02
FULL NAME OF THIRD INVENTOR		
RESIDENCE & CITIZENSHIP		COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS		
THIRD INVENTOR'S SIGNATURE		DATE

Listing of Inventors Continued on attached page(s): ☐ Yes ☒ No